|
[1]
|
Chinese Center for Disease Control and Prevention. National situation of novel coronavirus infection. 2023. https://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_13141/202304/t20230401_264798.html. [2023-6-11]. (In Chinese). |
|
[2]
|
Sheikh A, Kerr S, Woolhouse M, McMenamin J, Robertson C, EAVE II Collaborators. Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design. Lancet Infect Dis 2022;22(7):959 − 66. https://doi.org/10.1016/S1473-3099(22)00141-4CrossRef
|
|
[3]
|
Klein EY, Fall A, Norton JM, Eldesouki RE, Abdullah O, Han LJ, et al. Severity outcomes associated with SARS-CoV-2 XBB variants, an observational analysis. J Clin Virol 2023;165:105500. https://doi.org/10.1016/j.jcv.2023.105500CrossRef
|
|
[4]
|
Nguyen NN, Nguyen YN, Hoang VT, Million M, Gautret P. SARS-CoV-2 reinfection and severity of the disease: a systematic review and meta-analysis. Viruses 2023;15(4):967. https://doi.org/10.3390/v15040967CrossRef
|
|
[5]
|
COVID-19 Forecasting Team. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 2023;401(10379):833 − 42. https://doi.org/10.1016/S0140-6736(22)02465-5CrossRef
|
|
[6]
|
Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022;28(11):2398 − 405. https://doi.org/10.1038/s41591-022-02051-3CrossRef
|
|
[7]
|
Liu Y, Mao B, Liang S, Yang JW, Lu HW, Chai YH, et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur Respir J 2020;55(5):2001112. https://doi.org/10.1183/13993003.01112-2020CrossRef
|
|
[8]
|
Al-Numair NS, Alyounes B, Al-Saud H, Halwani R, Al-Muhsen S. Clinical characteristics, risk factors, and rate of severity of a nationwide COVID-19 Saudi cohort. Saudi J Biol Sci 2022;29(7):103315. https://doi.org/10.1016/j.sjbs.2022.103315CrossRef
|
|
[9]
|
Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol 2023;64(1):90 − 107. https://doi.org/10.1007/s12016-022-08921-5CrossRef
|
|
[10]
|
Bobrovitz N, Ware H, Ma XM, Li ZH, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 2023;23(5):556 − 67. https://doi.org/10.1016/S1473-3099(22)00801-5CrossRef
|